Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Published:2016-07 Issue:7 Volume:27 Page:1291-1298
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chatterjee M.,Turner D.C.,Felip E.,Lena H.,Cappuzzo F.,Horn L.,Garon E.B.,Hui R.,Arkenau H.-T.,Gubens M.A.,Hellmann M.D.,Dong D.,Li C.,Mayawala K.,Freshwater T.,Ahamadi M.,Stone J.,Lubiniecki G.M.,Zhang J.,Im E.,De Alwis D.P.,Kondic A.G.,Fløtten Ø.

Funder

Merck & Co., Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/7/1291/16698276/mdw174.pdf

Reference17 articles.

1. Population pharmacokinetics of therapeutic monoclonal antibodies;Dirks;Clin Pharmacokinet,2010

2. Population pharmacokinetic (popPK) model of pembrolizumab (pembo; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002;Gangadhar;J Clin Oncol,2015

3. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors;Patnaik;Clin Cancer Res,2015

4. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

5. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development;Wang;Clin Pharmacol Ther,2009

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained Settings;South Asian Journal of Cancer;2024-07-31

2. Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer;Cancers;2024-06-26

3. Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice;Journal of Pharmacokinetics and Pharmacodynamics;2024-06-21

4. Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories;Frontiers in Pharmacology;2024-06-04

5. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol;BMC Cancer;2024-05-23